Dermata Therapeutics, Inc. (DRMAW)

The immediate outlook is severely bearish due to a catastrophic collapse in share price, which has compressed the market capitalization to a fraction of its book value. While the company recently secured funding through private placements and raised capital for an acne kit product, the stock has effectively erased nearly all of that equity value, trading at a price that suggests the market has priced out any near-term recovery potential. The lack of recent price history prevents a meaningful assessment of the long-term trajectory, but the current fundamental reality—negative returns on assets and equity, coupled with a massive cash burn rate relative to the tiny market cap—indicates a high-risk speculative environment rather than a viable investment opportunity. There is no dividend income to offset these severe risks.